AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21895947 — intervention group
Group type: COMPARATOR
Intervention: Routine prenatal care programme (control group)
Number of subjects: 82
Study 19640734 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic agent (prilocaine 2%) plus 500 microg nitroglycerin (group A)
Number of subjects: 63
Study 19640734 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic agent (prilocaine 2%) (group B)
Number of subjects: 63
Study 17366257 — intervention group
Group type: EXPERIMENTAL
Intervention: Teleconferencing Supervision during 5 counseling sessions
Number of subjects: 13
Study 15662091 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/d)
Number of subjects: 63
Study 15662091 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (40 mg/d)
Number of subjects: 63
Study 11094579 — intervention group
Group type: COMPARATOR
Intervention: i.v. ondansetron 4 mg (control)
Number of subjects: 139
Study 11094579 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. ondansetron 4 mg and cyclizine 50 mg (combination)
Number of subjects: 139
Study 11094579 — intervention group
Group type: COMPARATOR
Intervention: i.v. saline 0.9% (placebo)
Number of subjects: 139
Study 8834689 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% tilt
Number of subjects: 33
Study 8834689 — intervention group
Group type: EXPERIMENTAL
Intervention: 65% tilt
Number of subjects: 33
Study 8834689 — intervention group
Group type: COMPARATOR
Intervention: 40% tilt
Number of subjects: 33
Study 1422320 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipriflavone (600 mg/day)
Number of subjects: 126
Study 1422320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 6362386 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepridil 300 mg/day
Number of subjects: 77
Study 6362386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 3550214 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (2 mg 6 hr‐1)
Number of subjects: 6
Study 3550214 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (40 mg day‐1) with prazosin
Number of subjects: 6
Study 3550214 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (40 mg day‐1) with prazosin and captopril (25 mg 6 hr‐1)
Number of subjects: 6
Study 3550214 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (40 mg day‐1) alone
Number of subjects: 6
Study 28961803 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐00547659 22.5 mg
Number of subjects: 0
Study 28961803 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐00547659 75 mg
Number of subjects: 0
Study 28961803 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐00547659 225 mg
Number of subjects: 0
Study 28961803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28961803 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐00547659
Number of subjects: 0
Study 26778925 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein diet (>3 g/kg/day)
Number of subjects: 12
Study 26778925 — intervention group
Group type: COMPARATOR
Intervention: Normal (habitual) diet (2.6 ± 0.8 g/kg/day)
Number of subjects: 12
Study 25246821 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadoxetic acid injection at 0.5 mL/s (n = 50)
Number of subjects: 101
Study 25246821 — intervention group
Group type: COMPARATOR
Intervention: Gadoxetic acid injection at 1 mL/s (n = 51)
Number of subjects: 101
Study 23810267 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention addressing individual needs related to asthma control, inhaler technique, and medication adherence
Number of subjects: 336
Study 23810267 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention
Number of subjects: 336
Study 23810267 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 336
Study 20971961 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam 20 mg IV over 30 minutes
Number of subjects: 12
Study 20971961 — intervention group
Group type: COMPARATOR
Intervention: Nefopam 20 mg IV over 30 minutes (healthy volunteers)
Number of subjects: 12
Study 18311576 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual physical examination, neck ultrasonography, and serum thyroid-stimulating hormone (TSH) measurement for patients undergoing thyroid lobectomy.
Number of subjects: 0
Study 18311576 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual physical examination and serum TSH measurement for patients undergoing total thyroidectomy.
Number of subjects: 0
Study 18311576 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine thyroxine and/or iodine supplementation for preventing recurrence in patients from iodine-deficient regions.
Number of subjects: 0
Study 15765200 — intervention group
Group type: EXPERIMENTAL
Intervention: AQUANOVA solubilisate (100 IU alpha-tocopheryl acetate and 400 mg crystalline vitamin C) in the form of vitaminized gummi bears
Number of subjects: 14
Study 15765200 — intervention group
Group type: COMPARATOR
Intervention: Reference products (conventional preparations)
Number of subjects: 14
Study 14597524 — intervention group
Group type: EXPERIMENTAL
Intervention: 8.0 mm grafts
Number of subjects: 797
Study 14597524 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mm grafts
Number of subjects: 797
Study 14597524 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.0 mm grafts
Number of subjects: 797
Study 14597524 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.0 mm grafts (all sutures out)
Number of subjects: 797
Study 14597524 — intervention group
Group type: EXPERIMENTAL
Intervention: Keratometric astigmatism (KA)
Number of subjects: 797
Study 14597524 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface Regularity Index (SRI)
Number of subjects: 797
Study 14597524 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface Asymmetry Index (SAI)
Number of subjects: 797
Study 14597524 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion of regular keratometry mires
Number of subjects: 797
Study 14597524 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion of not measurable keratometries
Number of subjects: 797
Study 14597524 — intervention group
Group type: EXPERIMENTAL
Intervention: SRI (all sutures out)
Number of subjects: 797
Study 14597524 — intervention group
Group type: EXPERIMENTAL
Intervention: SAI (all sutures out)
Number of subjects: 797
Study 14597524 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion of regular keratometry mires (all sutures out)
Number of subjects: 797
Study 14597524 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion of not measurable keratometries (all sutures out)
Number of subjects: 797
Study 10758988 — intervention group
Group type: EXPERIMENTAL
Intervention: JPEG compression ratio 10:1
Number of subjects: 48
Study 10758988 — intervention group
Group type: EXPERIMENTAL
Intervention: JPEG compression ratio 16:1
Number of subjects: 48
Study 10758988 — intervention group
Group type: EXPERIMENTAL
Intervention: JPEG compression ratio 6:1
Number of subjects: 48
Study 8703168 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (one month duration)
Number of subjects: 262
Study 8703168 — intervention group
Group type: COMPARATOR
Intervention: Placebo (one month duration)
Number of subjects: 262
Study 1578626 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine butylbromide (0.2 mg.kg-1)
Number of subjects: 42
Study 1578626 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine butylbromide (0.4 mg.kg-1)
Number of subjects: 42
Study 4092801 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% indomethacin solution applied 1 hour before UVB irradiation
Number of subjects: 0
Study 4092801 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin pretreatment
Number of subjects: 0
Study 4092801 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin applied before irradiation
Number of subjects: 0
Study 29128649 — intervention group
Group type: EXPERIMENTAL
Intervention: Web‐version of Prolonged Exposure (Web‐PE)
Number of subjects: 120
Study 29128649 — intervention group
Group type: COMPARATOR
Intervention: In-person Present‐Centered Therapy (PCT)
Number of subjects: 120
Study 27644242 — intervention group
Group type: EXPERIMENTAL
Intervention: ZinutriK® (4 weeks)
Number of subjects: 16
Study 25005045 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringerfundin® solution
Number of subjects: 44
Study 25005045 — intervention group
Group type: COMPARATOR
Intervention: Glucose/potassium‐based balanced crystalloid solution
Number of subjects: 44
Study 23000038 — intervention group
Group type: EXPERIMENTAL
Intervention: MIPPO technique
Number of subjects: 64
Study 23000038 — intervention group
Group type: COMPARATOR
Intervention: Conventional open reduction
Number of subjects: 64
Study 20797379 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher number of previous episodes
Number of subjects: 172
Study 20797379 — intervention group
Group type: EXPERIMENTAL
Intervention: More residual symptoms
Number of subjects: 172
Study 20797379 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower levels of positive refocusing
Number of subjects: 172
Study 19128589 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin therapy
Number of subjects: 68
Study 19128589 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric test
Number of subjects: 68
Study 19128589 — intervention group
Group type: EXPERIMENTAL
Intervention: VEMPs
Number of subjects: 68
Study 19128589 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 68
Study 15920378 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 24
Study 15920378 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 24
Study 12946545 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen ophthalmic solution (0.025%)
Number of subjects: 82
Study 12946545 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen with desloratadine
Number of subjects: 82
Study 12946545 — intervention group
Group type: COMPARATOR
Intervention: Desloratadine (5 mg tablets)
Number of subjects: 82
Study 12946545 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen ophthalmic solution
Number of subjects: 82
Study 12946545 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (ketotifen and desloratadine)
Number of subjects: 82
Study 10644288 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg once in the evening)
Number of subjects: 191
Study 10644288 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol (50 microg [2 puffs] twice daily)
Number of subjects: 191
Study 8738513 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic group (breast-fed with mothers excluding highly antigenic foods or given extensively hydrolysed formula)
Number of subjects: 120
Study 8738513 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic group
Number of subjects: 120
Study 8738513 — intervention group
Group type: COMPARATOR
Intervention: Control group (fed conventionally by breast or formula, no specific environmental measures)
Number of subjects: 120
Study 1362432 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (continuous infusion of 250 micrograms/h for 5 days plus daily bolus administration of 250 micrograms)
Number of subjects: 80
Study 1362432 — intervention group
Group type: COMPARATOR
Intervention: Injection sclerotherapy
Number of subjects: 80
Study 1362432 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 80
Study 3922510 — intervention group
Group type: COMPARATOR
Intervention: Nicotine gum with no further appointments (Control)
Number of subjects: 200
Study 3922510 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum with four further appointments over three months (Intervention)
Number of subjects: 200
Study 31183919 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's (LR)
Number of subjects: 50
Study 31183919 — intervention group
Group type: COMPARATOR
Intervention: 0.9% Normal Saline (NS)
Number of subjects: 50
Study 30326906 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management exercise program (5 sessions of 1.5 hours each) + information booklet + 18 sessions of spa therapy treatment (1 hour each)
Number of subjects: 0
Study 30326906 — intervention group
Group type: COMPARATOR
Intervention: Information booklet + 18 sessions of spa therapy treatment (1 hour each)
Number of subjects: 0
Study 30326906 — intervention group
Group type: COMPARATOR
Intervention: Information booklet + spa therapy
Number of subjects: 0
Study 27109450 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiroxostat 120 mg/day
Number of subjects: 206
Study 27109450 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol 200 mg/day
Number of subjects: 206
Study 25208075 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (n = 34)
Number of subjects: 75
Study 25208075 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training (n = 28)
Number of subjects: 75
Study 25208075 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic + resistance exercise training (n = 13)
Number of subjects: 75
Study 25208075 — intervention group
Group type: EXPERIMENTAL
Intervention: Detraining (following training)
Number of subjects: 75
Study 25208075 — intervention group
Group type: EXPERIMENTAL
Intervention: Training responders
Number of subjects: 75
Study 25208075 — intervention group
Group type: EXPERIMENTAL
Intervention: Training non-responders
Number of subjects: 75
Study 22166557 — intervention group
Group type: EXPERIMENTAL
Intervention: Balapiravir 500, 1000, or 1500 mg twice daily plus peginterferon alfa-2a (40KD)/ribavirin
Number of subjects: 516
Study 22166557 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon alfa-2a (40KD)/ribavirin
Number of subjects: 516
Study 22166557 — intervention group
Group type: EXPERIMENTAL
Intervention: Balapiravir
Number of subjects: 516
Study 22166557 — intervention group
Group type: EXPERIMENTAL
Intervention: Balapiravir/peginterferon alfa-2a/ribavirin combination
Number of subjects: 516
Study 20531106 — intervention group
Group type: EXPERIMENTAL
Intervention: Enema Casen (250 ml)
Number of subjects: 45
Study 20531106 — intervention group
Group type: COMPARATOR
Intervention: Fleet Enema (133 ml)
Number of subjects: 45
Study 20531106 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Enemas
Number of subjects: 45
Study 18549372 — intervention group
Group type: EXPERIMENTAL
Intervention: In-clinic rescue therapy (maximum of 2 visits per month)
Number of subjects: 200
Study 18549372 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (optimal self‐administered medical therapy)
Number of subjects: 200
Study 18549372 — intervention group
Group type: EXPERIMENTAL
Intervention: In-clinic rescue therapy
Number of subjects: 200
Study 18549372 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 200
Study 15909441 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavilon No Sting Barrier Film (NSBF)
Number of subjects: 35
Study 15909441 — intervention group
Group type: COMPARATOR
Intervention: Zinc paste compound
Number of subjects: 35
Study 12543286 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma chromogranin A levels (measured 3 days after onset of symptoms)
Number of subjects: 119
Study 12543286 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated chromogranin A level (cutoff, 24 ng/mL)
Number of subjects: 119
Study 10337883 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% nitrous oxide and 50% oxygen
Number of subjects: 22
Study 10337883 — intervention group
Group type: COMPARATOR
Intervention: 100% oxygen
Number of subjects: 22
Study 8659316 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparotomy by Pomeroy technique
Number of subjects: 43
Study 8659316 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy by Fallope rings
Number of subjects: 43
Study 8659316 — intervention group
Group type: EXPERIMENTAL
Intervention: Colpotomy by fimbriectomy
Number of subjects: 43
Study 8659316 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 43
Study 2140382 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (30 mg/day)
Number of subjects: 120
Study 2140382 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine (150 mg/day)
Number of subjects: 120
Study 6993671 — intervention group
Group type: EXPERIMENTAL
Intervention: Benoxaprofen
Number of subjects: 0
Study 6993671 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study 6993671 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 0
Study 6993671 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 0
Study 6993671 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 0
Study 6993671 — intervention group
Group type: COMPARATOR
Intervention: Sulindac
Number of subjects: 0
Study 31640452 — intervention group
Group type: EXPERIMENTAL
Intervention: Office-based vergence/accommodative therapy (OBVAT)
Number of subjects: 100
Study 31640452 — intervention group
Group type: COMPARATOR
Intervention: Office-based placebo therapy (OBPT)
Number of subjects: 100
Study 31640452 — intervention group
Group type: EXPERIMENTAL
Intervention: CI patients
Number of subjects: 100
Study 31640452 — intervention group
Group type: EXPERIMENTAL
Intervention: CI patients with comorbidity
Number of subjects: 100
Study 31129930 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP2205 10 mg
Number of subjects: 16
Study 31129930 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP2205 60 mg
Number of subjects: 16
Study 31129930 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 80 mg
Number of subjects: 16
Study 31129930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 28730680 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical stability training
Number of subjects: 50
Study 28730680 — intervention group
Group type: COMPARATOR
Intervention: Cervical-core stability training
Number of subjects: 50
Study 25200949 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational group
Number of subjects: 300
Study 25200949 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300
Study 24108780 — intervention group
Group type: EXPERIMENTAL
Intervention: EV71 vaccine (400 U of EV71 antigen)
Number of subjects: 1400
Study 24108780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1400
Study 21812557 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech sounds
Number of subjects: 0
Study 21812557 — intervention group
Group type: COMPARATOR
Intervention: Nonspeech mouth sounds (ingressive click)
Number of subjects: 0
Study 19485588 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifamily psychoeducation groups (MFPG)
Number of subjects: 165
Study 17000352 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental silicon liner (VL)
Number of subjects: 30
Study 17000352 — intervention group
Group type: COMPARATOR
Intervention: Dummy liner (PL)
Number of subjects: 30
Study 15592213 — intervention group
Group type: EXPERIMENTAL
Intervention: Bionator therapy
Number of subjects: 25
Study 15592213 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated Class II)
Number of subjects: 25
Study 11115338 — intervention group
Group type: EXPERIMENTAL
Intervention: Bile leakage test (injection of isotonic sodium chloride solution through the cystic duct)
Number of subjects: 103
Study 11115338 — intervention group
Group type: COMPARATOR
Intervention: No bile leakage test (control group)
Number of subjects: 103
Study 11115338 — intervention group
Group type: EXPERIMENTAL
Intervention: Bile leakage test
Number of subjects: 103
Study 9261307 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification with single- or two-quadrant conjunctival peritomy
Number of subjects: 74
Study 9261307 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 74
Study 9261307 — intervention group
Group type: COMPARATOR
Intervention: Single- or two-quadrant conjunctival peritomy
Number of subjects: 74
Study 7662225 — intervention group
Group type: EXPERIMENTAL
Intervention: bisoprolol (10 mg/day)
Number of subjects: 39
Study 7662225 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril (20 mg/day)
Number of subjects: 39
Study 7662225 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil SR (240 mg/day)
Number of subjects: 39
Study 7662225 — intervention group
Group type: COMPARATOR
Intervention: normotensive control subjects
Number of subjects: 39
Study 2758384 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening detected cancers
Number of subjects: 430
Study 2758384 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval cancers
Number of subjects: 430
Study 2758384 — intervention group
Group type: COMPARATOR
Intervention: Control group cancers
Number of subjects: 430
Study 2758384 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 430
Study 2758384 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumors with local recurrence
Number of subjects: 430
Study 2758384 — intervention group
Group type: EXPERIMENTAL
Intervention: Metastatic disease
Number of subjects: 430
Study 322827 — intervention group
Group type: EXPERIMENTAL
Intervention: Live-attenuated A/Hong Kong/68 (H3N2) influenza vaccine
Number of subjects: 71
Study 322827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 31977858 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicagrel 40 to 75 mg
Number of subjects: 67
Study 31977858 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicagrel 5 mg
Number of subjects: 67
Study 31977858 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg
Number of subjects: 67
Study 30940079 — intervention group
Group type: COMPARATOR
Intervention: 10 min algorithm
Number of subjects: 77
Study 30940079 — intervention group
Group type: EXPERIMENTAL
Intervention: Choi algorithm
Number of subjects: 77
Study 30940079 — intervention group
Group type: EXPERIMENTAL
Intervention: Troiano algorithm
Number of subjects: 77
Study 30940079 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min algorithm
Number of subjects: 77
Study 30940079 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 min algorithm
Number of subjects: 77
Study 30940079 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordance for MVPA assessment
Number of subjects: 77
Study 30940079 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 min algorithm
Number of subjects: 77
Study 28187226 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (D3) 60 micrograms (2400 IU)/d
Number of subjects: 35
Study 28187226 — intervention group
Group type: COMPARATOR
Intervention: Calcifediol (25D3) 20 μg/d
Number of subjects: 35